Clinical Trial Update: Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating bortezomib, rituximab, cyclophosphamide, and prednisone in relapsed or refractory indolent non-Hodgkin's lymphoma; results posted aft…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia, Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-11-20